Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors

This study has been completed.
Information provided by:
Mebiopharm Co., Ltd Identifier:
First received: July 24, 2006
Last updated: September 15, 2009
Last verified: September 2009

The purpose of this study is to determine whether MBP-426 (liposomal oxaliplatin suspension for injection) is safe and effective in the treatment of advanced or metastatic solid tumors.

Condition Intervention Phase
Drug: MBP-426
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Open Label Study of MBP-426 Given by Intravenous Infusion in Patients With Advanced or Metastatic Solid Tumors

Resource links provided by NLM:

Further study details as provided by Mebiopharm Co., Ltd:

Primary Outcome Measures:
  • Incidence of dose-limiting toxicity, determination of maximum tolerated dose (MTD), and recommended Phase 2 dose [ Time Frame: Within 21 days of treatment administration ] [ Designated as safety issue: Yes ]
  • Limited pharmacokinetics [ Time Frame: During Cycles 1 and 2; possibly at end of study, if necessary ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Tumor shrinkage according to RECIST [ Time Frame: Measured every 6 weeks (i.e., every 2 cycles) while receiving study drug ] [ Designated as safety issue: No ]
  • Limited exploratory assays [ Time Frame: Variable throughout study ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: June 2006
Study Completion Date: April 2009
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: MBP-426
Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.

Detailed Description:

Study Phase 1 Study Type (Interventional/Observational) Interventional Study Design Purpose: Treatment Allocation: Nonrandomized trial Masking: Open Control: Dose Comparison Assignment: Single Group Endpoint: Safety/Efficacy


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologically-confirmed malignancy that is locally advanced or metastatic solid tumor and is refractory to standard therapy or for which conventional therapy is not reliably effective or no effective therapy is available
  • 18 years of age or older
  • ECOG Performance Status of 0, 1, or 2
  • Adequate clinical laboratory values:

    • absolute neutrophil count greater than or equal to 1500 cells/microliter
    • platelets greater than or equal to 100,000 cells/microliter
    • serum creatinine less than or equal to 1.5 x upper limit of normal (ULN) for the institution
    • creatinine clearance (calculated) > 60 mL/min (using the Cockcroft-Gault equation)
    • bilirubin less than or equal to 1.5 x ULN
    • alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5 x ULN (patients with known liver metastases may have up to 5 times ULN AST and ALT levels).
  • Ability to cooperate with treatment and follow-up schedules
  • Negative pregnancy test and using at least one form of contraception as approved by the Investigator prior to study entry if a female patient of childbearing potential or a male patient with a female partner of childbearing potential
  • Measurable disease as defined by RECIST criteria or non-measurable disease
  • Patients with known brain metastases may be included as long as they have been clinically stable for one month or more, and are not receiving dexamethasone
  • Ability to maintain a central intravenous access (e.g. PICC, Groshong, or Hickman line)
  • Signed informed consent prior to the start of any study specific procedures

Exclusion Criteria:

  • Received previous anticancer chemotherapy, immunotherapy, radiotherapy or any other investigational therapy in the 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study entry
  • Received extensive prior radiotherapy to more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation
  • Any concomitant condition that could compromise the objectives of this study and the patient's compliance
  • Pregnant or lactating women
  • Current malignancies of another type, with the exception of adequately treated in situ cervical cancer and basal cell skin cancer or have demonstrated no evidence of disease for 5 years or more
  • Clinically evident HIV, HBV, or HCV infection
  • Hematologic malignancy
  • Documented or known bleeding disorder
  • Requirements for therapeutic anticoagulation that increases INR or aPTT above the normal range (low dose deep vein thrombosis [DVT] or line prophylaxis is allowed)
  • Congestive heart failure
  • Greater than Grade 1 peripheral neuropathy according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (CTCAE version 3.0)
  • History of allergic reactions to platinum-based or liposomal agents
  • Creatinine clearance (calculated) less than or equal to 60 mL/min (using the Cockcroft-Gault equation)
  • Receiving or initiating treatment with any other investigational agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00355888

United States, Texas
M.D. Anderson Cancer Center
Houston, Texas, United States, 77030-4009
Institute for Drug Development
San Antonio, Texas, United States, 78245
Sponsors and Collaborators
Mebiopharm Co., Ltd
Principal Investigator: Alexandria Phan, M.D. M.D. Anderson Cancer Center
  More Information

No publications provided

Responsible Party: Margaret Valnoski, President, Theradex, Inc. Identifier: NCT00355888     History of Changes
Other Study ID Numbers: M05-10070
Study First Received: July 24, 2006
Last Updated: September 15, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Mebiopharm Co., Ltd:
Advanced or Metastatic Solid Tumor processed this record on November 25, 2014